ClinicalTrials.gg
RecruitingNCT04556188RHD-CaSSUpdated Jun 12, 2025

The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa

An observational study in Rheumatic Heart Disease and Anticoagulant Adverse Reaction, sponsored by Helse Nord-Trøndelag HF. Recruiting at 4 sites in 2 countries. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Helse Nord-Trøndelag HF · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2016; still recruiting 10 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
14 Years and older
Sex
All
01

Study summary

In this bi-directional program of education, training and research activities based on sustainable development goals aim is to develop cardiac surgery service in Ethiopia.

The aim is to evaluate the short and long-term outcome of cardiac surgery for rheumatic heart disease in a low-income country compared to individuals not offered cardiac surgery due to limited availability of the service. Second aim is to evaluate the quality of anticoagulant therapy in patients after cardiac surgery for rheumatic heart disease in a low-income country .

Read the detailed description

Our objectives are:

  1. To evaluate the 30- and 180-days outcome of cardiac surgery for rheumatic heart disease (RHD), and impact of gender, age, clinical findings and echocardiographic classification, during the time of development of cardiac surgery at Black Lion hospital, Ethiopia, in comparison with matched individuals (from the same waiting list) which had no offer of surgery due to limited availability.
  2. To evaluate the quality of anticoagulation therapy after cardiac surgery at Black Lion hospital, Ethiopia by evaluating the patients proportion of time in therapeutic INR-level, complications as valve dysfunction, bleeding and thrombosis compared to control patients undergoing valvular replacement due to RHD at Norwegian hospitals.

Population: Approximately 50 RHD patients operated by Our team at Addis Abeba University Hospital, Ethiopia.

Follow up for 180-days for objective 1 and continous follow-up for objective 2. Comparison With matched Controls. Outcome measures: Mortality, complications (heart failure, arrhythmias, thrombosis, bleedings, stroke, infections)

02

Conditions studied

  • Rheumatic Heart Disease
  • Anticoagulant Adverse Reaction
03

In context

Rheumatic Heart Disease

62 studies on the registry are indexed under Rheumatic Heart Disease; 26 are open to participants now.

This study's planned enrollment of 200 is below the median of 1,423 across 23 observational studies indexed under Rheumatic Heart Disease.

Browse Rheumatic Heart Disease studies →

Lead sponsor

Helse Nord-Trøndelag HF is the lead sponsor of 27 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cases: Patients offered Cardiac surgery due to indication symptomatic rheumatic heart disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cardiac surgery due to rheumatic heart disease at the governmental Black Lion University Hospital during the bi-directional programme of education, training and Research to establish Cardiac surgery service

Exclusion criteria

Exclusion Criteria:

  • Not willing or able to provide written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cases

    RHD patients undergoing Cardiac surgery at Addis Abeba University Hospital

    Procedure: Cardiac surgery

  • RHD controls

    RHD patients not offered Cardiac surgery

  • Anticoagulation controls

    Norwegian patients on anticoagulant therapy due to mechanical valve implants

Interventions

  • ProcedureCardiac surgery
06

What researchers measure

Primary outcomes

  1. Short term outcome

    Freedom from Death or complication

    Time frame: 180 days

Other outcomes

  1. Time in therapeutic INR

    Time in therapeutic window (anticoagulation)

    Time frame: 2 years

  2. Mitral valve area by Doppler

    Influence of concomitant pathology for Echocardiographic assessment of mitral stenosis

    Time frame: 14 days

  3. Mitral phenotype in rheumatic heart disease

    Influence of mitral valve phenotype with cardiac morphology and complications in untreated rheumatic heart disease patients

    Time frame: 0 days

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Hauge SW, Dalen H, Estensen ME, Persson RM, Abebe S, Mekonnen D, Nega B, Solholm A, Farstad M, Bogale N, Graven T, Nielssen NE, Brekke HK, Vikenes K, Haaverstad R. Short-term outcome after open-heart surgery for severe chronic rheumatic heart disease in a low-income country, with comparison with an historical control group: an observational study. Open Heart. 2021 Aug;8(2):e001706. doi: 10.1136/openhrt-2021-001706. PubMed 34376574 ↗

Individual participant data

Plan to share: Undecided — No written plan. Under discussion.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2016 (actual). Primary completion is estimated for Dec 2025, 117 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2020
First posted
Sep 21, 2020
StartActual
Mar 1, 2016
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04556188
Lead sponsor
Helse Nord-Trøndelag HF
Collaborators
Haukeland University Hospital, Addis Ababa University
Responsible party
Sponsor
First posted
Sep 21, 2020
Start date
Mar 1, 2016
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jun 12, 2025

Study contacts

Haavard Dalen, MD, PhD
Contact
havard.dalen@ntnu.no
74098206 ext. 0047
Rune Haaverstad, MD, PhD
Contact
rune.haaverstad@helse-bergen.no
55 97 22 20 ext. 0047

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion